(E)-1,5-bis(3,4-dimethoxyphenyl)pent-1-en-3-one | 1217503-44-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-1,5-bis(3,4-dimethoxyphenyl)pent-1-en-3-one
• 英文别名: GO-Y087；1,5-bis(3,4-dimethoxyphenyl)-3-oxo-1-pentene
• CAS: 1217503-44-0
• 化学式: C₂₁H₂₄O₅
• 分子量: 356.419
• InChiKey: BWABBAUBCCBXSI-WEVVVXLNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 palladium diacetate 作用下， 以 乙腈 为溶剂， 生成 (E)-1,5-bis(3,4-dimethoxyphenyl)pent-1-en-3-one
  参考文献：
  名称：

  Structure–activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof

  摘要：

  A series of novel analogues of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-(1E,4E)-1,4-dien-3-one (C-5-curcumin), which is a natural analogue of curcumin isolated from the rhizomes of Curcuma domestica Val. (Zingiberacea), were synthesized and evaluated for their cytotoxicities against human colon cancer cell line HCT-116 to conclude the SAR of C-5-curcuminoids for further development of their use in cancer chemotherapy: (1) Bis(arylmethylidene) acetone serves as a promising skeleton for eliciting cytotoxicity. (2) The 3-oxo-1,4-pentadiene structure is essential for eliciting cytotoxicity. (3) As for the extent of the aromatic substituents, hexasubstituted compounds exhibit strong activities, in which 3,4,5-hexasubstitution results in the highest potency. (5) The symmetry between two aryl rings is not an essential requirement for bis(arylmethylidene) acetones to elicit cytotoxicity. (6) para-Positions allows the installation of additional functional groups for use as molecular probes. By taking advantage of the SAR diagram, we have elaborated several advanced derivatives having GI(50) of single-digit micromolar potencies that will function as molecular probes to target and/or report key biomolecules interacting with curcumin and C-5-curcumin. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.045

文献信息

• Curcumin analogs with anti-tumor and anti-angiogenic properties
  申请人：——

  公开号：US20020019382A1

  公开（公告）日：2002-02-14

  The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.

  本发明涉及表现出抗肿瘤和抗血管生成特性的姜黄素类似物，包括这些化合物的药物配方以及使用这些化合物的方法。
• [EN] CURCUMIN ANALOGUES FOR TREATING CANCER<br/>[FR] ANALOGUES DE CIRCUMINE DESTINES AU TRAITEMENT DU CANCER
  申请人：UNIV EMORY

  公开号：WO2001040188A1

  公开（公告）日：2001-06-07

  The present invention is directed to curcumin analogs (I), wherein Y is OH, halogen, or CF3; Z is H, OH, OR1, halogen, or CF3; X1 and X2 are independently C or N; and A is as defined in the application; exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.

  本发明涉及姜黄素类似物(I)，其中Y为OH、卤素或CF3；Z为H、OH、OR1、卤素或 ；X1和X2独立地为C或N；A如本申请所定义；该类似物具有抗肿瘤和抗血管生成作用，制备包括这些化合物的制药组合物以及使用这些化合物的方法。
• CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES
  申请人：Snyder James P.

  公开号：US20080234320A1

  公开（公告）日：2008-09-25

  The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.

  本发明涉及展现抗肿瘤和抗血管生成特性的姜黄素类似物，包括这些化合物的制药配方和使用这些化合物的方法。
• A lipoxygenase inhibitor
  申请人：GREEN CROSS CORPORATION

  公开号：EP0163270A2

  公开（公告）日：1985-12-04

  A lipoxygenase inhibitor comprising as active ingredient a substituted styrene derivative having a radical of the general formula wherein X denotes a hydroxyl group or a lower alkoxy group and q is an integer of 2 or 3, and containing carbon atoms in total of at least 8.

  一种脂氧合酶抑制剂，其活性成分包括具有通式基团的取代苯乙烯衍生物，其中 X 表示羟基或低级烷氧基，q 为 2 或 3 的整数，且总共含有至少 8 个碳原子。
• Methods and compositions for preserving retinal ganglion cells
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US10617735B2

  公开（公告）日：2020-04-14

  Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

  本发明提供了维持患有眼部疾病（例如青光眼和视神经损伤）的患者视网膜神经节细胞活力的方法和组合物。通过向患有眼部疾病的患者单独施用坏死抑制剂或与凋亡抑制剂联合施用，可保持视网膜神经节细胞的活力。给药后，组合物可维持细胞的活力和/或促进轴突再生，从而最大程度地减少与眼部疾病相关的视力或视觉功能的丧失。